LEXARIA BIOSCIENCE CORP. Deferred Revenue, Revenue Recognized
LEXARIA BIOSCIENCE CORP. (LEXX) reported Deferred Revenue, Revenue Recognized of $0 for the 12-month period ending 2019-08-31, per its 10-K filed 2019-11-14.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2019-11-14
- LEXARIA BIOSCIENCE CORP. deferred revenue, revenue recognized for the quarter ending 2018-11-30 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. deferred revenue, revenue recognized for the quarter ending 2017-11-30 was $6.25K.
- LEXARIA BIOSCIENCE CORP. deferred revenue, revenue recognized for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- LEXARIA BIOSCIENCE CORP. deferred revenue, revenue recognized for fiscal 2018 was $17.08K, a 43.65% decline from fiscal 2017.
- LEXARIA BIOSCIENCE CORP. deferred revenue, revenue recognized for fiscal 2017 was $30.32K.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2019-08-31 | $0.00 10-K · filed 2019-11-14 | |||
| 2019-05-31 | $0.00 10-Q · filed 2019-07-08 | |||
| 2018-11-30 | $0.00 10-Q · filed 2019-01-11 | |||
| 2018-08-31 | $17.08K 10-K · filed 2019-11-14 | |||
| 2018-05-31 | $17.08K 10-Q · filed 2018-07-13 | |||
| 2018-02-28 | $17.08K 10-Q · filed 2018-04-12 | |||
| 2017-11-30 | $6.25K 10-Q · filed 2018-01-12 | |||
| 2017-08-31 | $30.32K 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |